
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma is attractive because ronde-cel has shown differentiated efficacy in LBCL, with a 77% complete response rate, 91% ORR, and estimated 12-month PFS of 63%, while safety remains favorable with no Grade ≥3 CRS in the reported PiNACLE patients and only 9% Grade ≥3 ICANS. Its commercial case is strengthened by the possibility that roughly half of LBCL CAR-T collections could qualify for a 3L+ label, supported by 98% manufacturing success, a 16-day median vein-to-site time, and a LyFE platform expected to support more than 3,000 doses annually. Financially, the recent $80M financing extends expected cash runway into 2028, giving the company time to reach the planned 2H27 BLA submission and to advance LYL273 as an additional value driver in mCRC and other GCC-expressing cancers.
Bears say
Lyell Immunopharma is a high-risk, pre-commercial cell therapy developer whose outlook is weighed down by meaningful clinical, regulatory, and financing uncertainty across its CAR-T pipeline. The bear case assumes safety issues or regulatory headwinds could delay filings and reduce the probability of success for ronde-cel to 15% in DLBCL and LYL273 to 5%, while LYL273’s CARABINer updates and End-of-Phase I FDA meeting were pushed to 2027 from 2H:26. With no FDA or EMA approvals, intense competition in LBCL and mCRC, likely reimbursement pressure, and a need for additional funding that may not be available on favorable terms, execution risk remains elevated.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Lyell Immunopharma (LYEL) Forecast
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares